Your search for tofacitinib returned 17 results

The ORAL Shift study enrolled 694 RA patients who were inadequate responders to methotrexate alone.

Pfizer announced detailed results from the first 2 pivotal Phase 3 trials of the OCTAVE program evaluating oral tofacitinib 10mg twice daily in inducing remission in adults with moderately to severely active ulcerative colitis (UC). Findings were orally presented at the 11th Congress of ECCO Scientific Session.

Pfizer announced top-line results from two Phase 3 induction trials of tofacitinib for the treatment of adults with moderate to severe ulcerative colitis (UC).

Pfizer announced results from two Phase 3 studies from the Oral treatment Psoriasis Trials (OPT) program for tofacitinib citrate in adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Pfizer announced results from the OPT (Oral treatment Psoriasis Trial) Retreatment study (A3921111) assessing tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis.

Pfizer announced top-line results from two pivotal Phase 3 trials, evaluating the efficacy and safety of Xeljanz (tofacitinib) for the treatment of moderate-to-severe plaque psoriasis.

Pfizer announced top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib in the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

Pfizer announced that the FDA has accepted for review its New Drug Application (NDA) for tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The NDA is based on previously completed Phase 3 trials.

The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for upadacitinib (AbbVie), an investigational oral JAK1-selective inhibitor, for the treatment of moderate to severe rheumatoid arthritis (RA).